Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.36 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.36 |
| ▸ | PGK1 | P00558 | 1/20 | 0.35 |
| ▸ | PGK2 | P07205 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 2/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18415006 | 1.00 | IRAK4 (0.38) | IRAK4S1PR2S1PR4S1PR3PGK1 | |
| SCHEMBL30577788 | 0.84 | IRAK4 (0.41) | IRAK4S1PR2S1PR4S1PR3PGK1 | |
| SCHEMBL906775 | 0.84 | IRAK4 (0.41) | IRAK4S1PR2S1PR4S1PR3PGK1 | |
| SCHEMBL21264174 | 0.83 | IRAK4 (0.37) | IRAK4S1PR2S1PR4S1PR3PGK1 | |
| SCHEMBL29413191 | 0.82 | S1PR2 (0.38) | IRAK4S1PR2S1PR4S1PR3PGK1 | |
| SCHEMBL104442 | 0.82 | S1PR2 (0.38) | IRAK4S1PR2S1PR4S1PR3PGK1 | |
| SCHEMBL13762868 | 0.80 | S1PR2 (0.41) | IRAK4S1PR2S1PR4S1PR3HTR7 | |
| SCHEMBL1022830 | 0.80 | S1PR2 (0.41) | IRAK4S1PR2S1PR4S1PR3HTR7 | |
| SCHEMBL400366 | 0.78 | IRAK4 (0.38) | IRAK4S1PR2S1PR4S1PR3PGK1 | |
| SCHEMBL2036719 | 0.78 | IRAK4 (0.38) | IRAK4S1PR2S1PR4S1PR3PGK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304577-A1 | TYK2 INHIBITORS | BIOGEN MA INC. | 2025-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304577-A1 | TYK2 INHIBITORS | TYK2, JAK2, JAK1 | IRAK4 163/4885S1PR2 1555/4885S1PR4 3165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.